Michael Lundemann1, Junia Cardoso Costa2, Ian Law3, Svend Aage Engelholm4, Aida Muhic5, Hans Skovgaard Poulsen5, Per Munck Af Rosenschold6. 1. Department of Oncology, Section of Radiotherapy, Rigshospitalet, Copenhagen University Hospital, København Ø, Denmark; Niels Bohr Institute, Department of Science, University of Copenhagen, København Ø, Denmark. Electronic address: michael.lundemann.jensen@regionh.dk. 2. Department of Oncology, Section of Radiotherapy, Rigshospitalet, Copenhagen University Hospital, København Ø, Denmark; Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen University Hospital, København Ø, Denmark. 3. Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen University Hospital, København Ø, Denmark. 4. Department of Oncology, Section of Radiotherapy, Rigshospitalet, Copenhagen University Hospital, København Ø, Denmark. 5. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, København Ø, Denmark. 6. Department of Oncology, Section of Radiotherapy, Rigshospitalet, Copenhagen University Hospital, København Ø, Denmark; Niels Bohr Institute, Department of Science, University of Copenhagen, København Ø, Denmark.
Abstract
BACKGROUND AND PURPOSE: To evaluate the patterns of failure following clinical introduction of amino-acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET-guided target definition for radiotherapy (RT) of glioblastoma patients. MATERIALS AND METHODS: The first 66 consecutive patients with confirmed histology, scanned using FET-PET/CT and MRI were selected for evaluation. Chemo-radiotherapy was delivered to a volume based on both MRI and FET-PET (PETvol). The volume of recurrence (RV) was defined on MRI data collected at the time of progression according to RANO criteria. RESULTS: Fifty patients were evaluable, with median follow-up of 45months. Central, in-field, marginal and distant recurrences were observed for 82%, 10%, 2%, and 6% of the patients, respectively. We found a volumetric overlap of 26%, 31% and 39% of the RV with the contrast-enhancing MR volume, PETvol and the composite MRPETvol, respectively. MGMT-methylation (p=0.03), larger PETvol (p<0.001), and less extensive surgery (p<0.001), were associated with larger PETvol overlap. CONCLUSION: The combined MRPETvol had a stronger association with the recurrence volume than either of the modalities alone. Larger overlap of PETvol and RV was observed for patients with MGMT-methylation, less extensive surgery, and large PETvol on the RT-planning scans.
BACKGROUND AND PURPOSE: To evaluate the patterns of failure following clinical introduction of amino-acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET-guided target definition for radiotherapy (RT) of glioblastomapatients. MATERIALS AND METHODS: The first 66 consecutive patients with confirmed histology, scanned using FET-PET/CT and MRI were selected for evaluation. Chemo-radiotherapy was delivered to a volume based on both MRI and FET-PET (PETvol). The volume of recurrence (RV) was defined on MRI data collected at the time of progression according to RANO criteria. RESULTS: Fifty patients were evaluable, with median follow-up of 45months. Central, in-field, marginal and distant recurrences were observed for 82%, 10%, 2%, and 6% of the patients, respectively. We found a volumetric overlap of 26%, 31% and 39% of the RV with the contrast-enhancing MR volume, PETvol and the composite MRPETvol, respectively. MGMT-methylation (p=0.03), larger PETvol (p<0.001), and less extensive surgery (p<0.001), were associated with larger PETvol overlap. CONCLUSION: The combined MRPETvol had a stronger association with the recurrence volume than either of the modalities alone. Larger overlap of PETvol and RV was observed for patients with MGMT-methylation, less extensive surgery, and large PETvol on the RT-planning scans.
Authors: Michael Lundemann; Per Munck Af Rosenschöld; Aida Muhic; Vibeke A Larsen; Hans S Poulsen; Svend-Aage Engelholm; Flemming L Andersen; Andreas Kjær; Henrik B W Larsson; Ian Law; Adam E Hansen Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-02 Impact factor: 9.236
Authors: Robert Kosztyla; Srinivas Raman; Vitali Moiseenko; Stefan A Reinsberg; Brian Toyota; Alan Nichol Journal: Br J Radiol Date: 2019-05-14 Impact factor: 3.039
Authors: M Back; D Jayamanne; D Brazier; A Newey; D Bailey; G Schembri; E Hsiao; M Khasraw; M Wong; M Kastelan; C Brown; H Wheeler Journal: Strahlenther Onkol Date: 2019-04-26 Impact factor: 4.033
Authors: Daniel F Fleischmann; Marcus Unterrainer; Stefanie Corradini; Maya Rottler; Stefan Förster; Christian la Fougère; Timo Siepmann; Markus Schwaiger; Peter Bartenstein; Claus Belka; Nathalie L Albert; Maximilian Niyazi Journal: PLoS One Date: 2019-07-24 Impact factor: 3.240
Authors: M Unterrainer; C Eze; H Ilhan; S Marschner; O Roengvoraphoj; N S Schmidt-Hegemann; F Walter; W G Kunz; P Munck Af Rosenschöld; R Jeraj; N L Albert; A L Grosu; M Niyazi; P Bartenstein; C Belka Journal: Radiat Oncol Date: 2020-04-21 Impact factor: 3.481